# Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

> **NCT05313243** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 32 (estimated)

## Conditions studied

- T-Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05313243
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313243, "Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05313243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*